Cargando…
Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review
Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by com...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922364/ https://www.ncbi.nlm.nih.gov/pubmed/35299752 http://dx.doi.org/10.3389/fonc.2022.816903 |
_version_ | 1784669510347784192 |
---|---|
author | Chen, Nanxiang Ba, Wei Zhao, Dawei Sheng, Lei Zhang, Xinxin |
author_facet | Chen, Nanxiang Ba, Wei Zhao, Dawei Sheng, Lei Zhang, Xinxin |
author_sort | Chen, Nanxiang |
collection | PubMed |
description | Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by complete surgical resection. Adjuvant chemotherapy and radiotherapy are alternative methods. Immune checkpoint inhibitors (ICIs) represented by the programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) antibody have achieved significant clinical benefits in a variety of solid tumors. However, reports on the treatment of FDCS with ICIs are rare. FDCS often expresses high levels of PD-L1, which provides a rationale to use immunotherapy in cases of FDCS. Here, we present a 51-year-old Filipino-Chinese man with FDCS who was treated with multimodal treatment, including the PD-1 inhibitor pembrolizumab and achieved a relatively long disease-free survival of 24 months. This case emphasizes that the application of ICIs under the guidance of NGS technology seems to be a meaningful treatment option for patients with FDCS. |
format | Online Article Text |
id | pubmed-8922364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89223642022-03-16 Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review Chen, Nanxiang Ba, Wei Zhao, Dawei Sheng, Lei Zhang, Xinxin Front Oncol Oncology Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by complete surgical resection. Adjuvant chemotherapy and radiotherapy are alternative methods. Immune checkpoint inhibitors (ICIs) represented by the programmed death receptor 1/programmed death ligand 1 (PD-1/PD-L1) antibody have achieved significant clinical benefits in a variety of solid tumors. However, reports on the treatment of FDCS with ICIs are rare. FDCS often expresses high levels of PD-L1, which provides a rationale to use immunotherapy in cases of FDCS. Here, we present a 51-year-old Filipino-Chinese man with FDCS who was treated with multimodal treatment, including the PD-1 inhibitor pembrolizumab and achieved a relatively long disease-free survival of 24 months. This case emphasizes that the application of ICIs under the guidance of NGS technology seems to be a meaningful treatment option for patients with FDCS. Frontiers Media S.A. 2022-03-01 /pmc/articles/PMC8922364/ /pubmed/35299752 http://dx.doi.org/10.3389/fonc.2022.816903 Text en Copyright © 2022 Chen, Ba, Zhao, Sheng and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chen, Nanxiang Ba, Wei Zhao, Dawei Sheng, Lei Zhang, Xinxin Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review |
title | Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review |
title_full | Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review |
title_fullStr | Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review |
title_full_unstemmed | Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review |
title_short | Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review |
title_sort | response of tonsil follicular dendritic cell sarcoma to multimodal treatment including pembrolizumab: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922364/ https://www.ncbi.nlm.nih.gov/pubmed/35299752 http://dx.doi.org/10.3389/fonc.2022.816903 |
work_keys_str_mv | AT chennanxiang responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview AT bawei responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview AT zhaodawei responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview AT shenglei responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview AT zhangxinxin responseoftonsilfolliculardendriticcellsarcomatomultimodaltreatmentincludingpembrolizumabacasereportandliteraturereview |